Rethinking chronic kidney disease risk after liver transplantation

Table 2 Comparative profile of tacrolimus vs cyclosporine A post-liver transplantation

Ref.	Clinical outcome	TAC profile (relative to CsA)	CsA profile (relative to TAC)	Supporting evidence type
Muduma et al[12], 2016	Patient mortality	Superior/Lower risk	Higher risk	RCTs/meta-analysis
Muduma et al[12], 2016	New-onset diabetes (NODAT)	Higher risk	Superior/Lower risk	RCTs/meta-analysis
Randhawa et al[11], 1997; Muduma et al[12], 2016	Hypertension	Superior/Lower risk	Higher risk	RCTs/meta-analysis
Muduma et al[12], 2016	Graft loss (overall)	Equivalent	Equivalent	RCTs/meta-analysis
Muduma et al[12], 2016	Graft loss (HCV subgroup)	Higher risk	Superior/Lower risk	Meta-analysis

CsA: Cyclosporine A; HCV: Hepatitis C virus; LT: Liver transplantation; NODAT: New-onset diabetes after transplantation; RCTs: Randomized controlled trials; TAC: Tacrolimus.